In 2013, Tembhre et al. detected increased serum levels of IL-10, IL-13, and IL-17A and decreased concentrations of TGF-β1 in patients with vitiligo and that might facilitate the melanocyte cytotoxicity; meanwhile treatment with NB-UVB was capable of elevating TGF-β levels, suggesting that Treg cytokines might play an important role in repigmentation [30]. The gene discussed is TGFB1; the disease is vitiligo.